Compare VanEck Rare Earth/Strategic Metals (REMX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Rare Earth/Strategic Metals vs Twist Bioscience Corp — how do they compare? VanEck Rare Earth/Strategic Metals trades at $75.61, while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| REMX | TWST | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $109.53 | $153.10 |
52-Week Low | $57.35 | $24.16 |
Market Cap | — | $8.42B |
Enterprise Value | — | $8.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
REMX trades at $76.72, up 1.4% today, but technical indicators show a bearish trend with moving averages signaling caution. The ETF faces high volatility (~50% annualized) and significant portfolio turnover, making it unsuitable for conservative investors. Recent news highlights institutional interest with Bank of America increasing its stake by 72.1% in the latest quarter (Defense World, August 14, 2026).
The outlook for REMX is mixed—geopolitical tensions and U.S. efforts to secure rare earth supply chains offer long-term potential, but high volatility and China-dependent holdings pose risks. Investors should weigh strategic exposure against the ETF's aggressive risk profile and monitor tariff policies impacting the sector.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
